GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Bio Medica Corp (OTCPK:ABMC) » Definitions » Beneish M-Score

American Bio Medica (American Bio Medica) Beneish M-Score : 0.00 (As of May. 03, 2024)


View and export this data going back to . Start your Free Trial

What is American Bio Medica Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for American Bio Medica's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of American Bio Medica was 0.00. The lowest was 0.00. And the median was 0.00.


American Bio Medica Beneish M-Score Historical Data

The historical data trend for American Bio Medica's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Bio Medica Beneish M-Score Chart

American Bio Medica Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.61 -4.72 -3.16 -2.82 -7.36

American Bio Medica Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.81 -7.06 -7.52 -7.36 -6.53

Competitive Comparison of American Bio Medica's Beneish M-Score

For the Diagnostics & Research subindustry, American Bio Medica's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Bio Medica's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Bio Medica's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where American Bio Medica's Beneish M-Score falls into.



American Bio Medica Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of American Bio Medica for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.4944+0.528 * -2.9456+0.404 * 0+0.892 * 0.362+0.115 * 0.1107
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.9421+4.679 * -0.259484-0.327 * 0.9233
=-6.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Total Receivables was $0.29 Mil.
Revenue was 0.164 + 0.167 + 0.209 + 0.185 = $0.73 Mil.
Gross Profit was 0.074 + -0.05 + -0.009 + -0.073 = $-0.06 Mil.
Total Current Assets was $0.66 Mil.
Total Assets was $0.66 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.05 Mil.
Selling, General, & Admin. Expense(SGA) was $0.98 Mil.
Total Current Liabilities was $1.12 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was 1.881 + -0.317 + -0.314 + -0.4 = $0.85 Mil.
Non Operating Income was 2.114 + 0.023 + 0.001 + 0.001 = $2.14 Mil.
Cash Flow from Operations was -0.363 + -0.611 + -0.075 + -0.069 = $-1.12 Mil.
Total Receivables was $0.54 Mil.
Revenue was 0.351 + 0.509 + 0.614 + 0.529 = $2.00 Mil.
Gross Profit was 0.028 + 0.123 + 0.185 + 0.136 = $0.47 Mil.
Total Current Assets was $1.04 Mil.
Total Assets was $1.57 Mil.
Property, Plant and Equipment(Net PPE) was $0.51 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.06 Mil.
Selling, General, & Admin. Expense(SGA) was $1.39 Mil.
Total Current Liabilities was $2.87 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.291 / 0.725) / (0.538 / 2.003)
=0.401379 / 0.268597
=1.4944

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.472 / 2.003) / (-0.058 / 0.725)
=0.235647 / -0.08
=-2.9456

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.659 + 0) / 0.659) / (1 - (1.038 + 0.506) / 1.565)
=0 / 0.013419
=0

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.725 / 2.003
=0.362

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.063 / (0.063 + 0.506)) / (0.046 / (0.046 + 0))
=0.110721 / 1
=0.1107

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0.975 / 0.725) / (1.387 / 2.003)
=1.344828 / 0.692461
=1.9421

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 1.117) / 0.659) / ((0.002 + 2.871) / 1.565)
=1.694992 / 1.835783
=0.9233

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(0.85 - 2.139 - -1.118) / 0.659
=-0.259484

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

American Bio Medica has a M-score of -6.53 suggests that the company is unlikely to be a manipulator.


American Bio Medica Beneish M-Score Related Terms

Thank you for viewing the detailed overview of American Bio Medica's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


American Bio Medica (American Bio Medica) Business Description

Traded in Other Exchanges
N/A
Address
122 Smith Road, Kinderhook, New York, NY, USA, 12106
American Bio Medica Corp is a us-based company engaged in manufacturing and selling lateral flow immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids at the point of collection. It also manufactures and sells drug testing products and provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. The company offers few urine tests which include Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II. Its target customer includes workplace, government, corrections, clinical and educational markets. Geographically, it derives a majority of revenue from the United States.
Executives
Stuart Steinberg 10 percent owner 85 BELLEVUE AVENUE, RYE NY 10580
John J Moroney 10 percent owner 118 PEGASUS DR., JUPITER FL 33477
Chaim Davis director 2601 PINE TREE DRIVE, MIAMI BEACH FL 33140
Peter Jerome director 7 RIDGECREST AVE, LATHAM NY 12110
Diane Generous director 122 SMITH ROAD, KINDERHOOK NY 12106
Melissa A Waterhouse officer: EVP, CCO, CORP SEC AMERICAN BIO MEDICA CORPORATION, 122 SMITH ROAD, KINDERHOOK NY 12106
Mp Biomedicals Llc 10 percent owner 3 HUTTON CENTRE DRIVE, SUITE 100, SANTA ANA CA 92707
Douglas Casterlin officer: Executive Vice President C/O MELISSA A. WATERHOUSE/ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Jean Neff director C/O ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Stefan Parker officer: Chief Financial Officer 122 SMITH ROAD, KINDERHOOK NY 12106
Carl A Florio director C/O HUDSON RIVER BANK & TRUST CO, PO BOX 76, HUDSON NY 12534
Stan Cipkowski director 300 S LAKE DR, STE 340, FISHKILL NY 12553
Anthony G Costantino director 122 SMITH ROAD, KINDERHOOK NY 12106
Edmund M Jaskiewicz director, officer: President
Richard Koskey director C/O ABMC 122 SMITH ROAD, 122 SMITH ROAD, KINDERHOOK NY 12106

American Bio Medica (American Bio Medica) Headlines